https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-eosinophilic-esophagitis-likelihood-of-approval/
IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase II for Eosinophilic Esophagitis.
eosinophilic esophagitisirlrevolobiotherapeuticslikelihood